What question did this study set out to answer?

The aim is to investigate the clinical outcomes of monoclonal gammopathy of renal significance (MGRS) in a large cohort, focusing on amyloidosis cases.

February 14, 2026Open Access

Monoclonal gammopathy of renal significance in western China: A large cohort study dominated by amyloidosis with distinct clinical outcomes

Key Points

The aim is to investigate the clinical outcomes of monoclonal gammopathy of renal significance (MGRS) in a large cohort, focusing on amyloidosis cases.
Examined a large cohort of MGRS patients in Western China.
Categorized patients based on amyloidosis and non-amyloidosis (MGRS-A and MGRS-NA).
Analyzed therapeutic responses and their impact on both hematologic and renal outcomes.
Amyloidosis was identified as the main cause of kidney injury in MGRS cases.
Patients with MGRS-A had a worse prognosis compared to those with MGRS-NA.
Key prognostic markers included age and cardiac involvement, influencing renal and patient survival.

Abstract

MGRS represents a clinically significant cause of kidney injury in monoclonal gammopathy patients, with amyloidosis being the predominant etiology. MGRS-A portends a worse prognosis than MGRS-NA. Therapeutic responses in both hematologic and renal parameters predict survival benefits. Age and cardiac involvement emerge as key prognostic markers for both renal and patient survival.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wang et al. (Thu,) studied this question.

synapsesocial.com/papers/699010382ccff479cfe56bf2 https://doi.org/https://doi.org/10.1016/j.clinsp.2026.100866

Bookmark

View Full Paper